20-quarter listed-company comparison

Diagnostics Stocks in India

Diagnostics: Dr Lal Pathlabs Ltd owns the largest revenue base; One Global Service Provider Ltd has the fastest current growth.

The 9 Diagnostics companies listed in India are Dr Lal Pathlabs Ltd (₹32.0K Cr, the largest), Vijaya Diagnostic Centre Ltd, Metropolis Healthcare Ltd and 6 more. 8 of 9 covered companies beat NIFTY 500 on relative strength. Readings are as of 17 Sep 2026.

All 9 Diagnostics Stocks in India (Sep 2026) — ranked by 4-Factor score

1One Global Service Provider Ltd₹1.1K Cr74.9/100Favorable setup · strongest on ROCE and profit growth
2Thyrocare Technologies Ltd₹8.7K Cr68.3/100Favorable setup · strongest on ROCE and profit growth
3Metropolis Healthcare Ltd₹12.1K Cr62.3/100Mixed-positive evidence · strongest on PEG and profit growth
4Dr Lal Pathlabs Ltd₹32.0K Cr58.8/100Mixed-positive evidence · strongest on ROCE and relative strength versus sector
5Vijaya Diagnostic Centre Ltd₹15.5K Cr55.7/100Mixed-positive evidence · strongest on relative strength versus sector and margin improvement
6Suraksha Diagnostic Ltd₹1.7K Cr52.3/100Mixed-positive evidence · strongest on 13-week relative-strength change and revenue growth
73B Blackbio DX Ltd₹1.2K Cr51.1/100Mixed-positive evidence · strongest on ROCE and revenue growth
8Vimta Labs Ltd₹2.8K Cr36.6/100Mixed-negative evidence · strongest on ROCE and operating margin
9Krsnaa Diagnostics Ltd₹1.8K Cr36.5/100Mixed-negative evidence · strongest on own-history P/E and sector-relative P/E

Ranked by the 4-Factor Sector Score (growth & earnings 35, capital efficiency 25, valuation 20, relative strength 20). Prices as of 11 Sep 2026. Not investment advice.

01 · the index people search for

Nifty Diagnostics Index — Constituents & Performance

All 9 listed Indian Diagnostics companies are named here, largest first — the same constituent set people search for as the Nifty Diagnostics index. Every figure is equal-weighted across those companies and carries its own as-of date. One large constituent cannot set the reading.

02 · the sector itself · before any single company

How has Diagnostics moved against NIFTY 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this sector is 80% ahead of NIFTY 500. Earnings across its companies grew 19% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 16 weeks running.

LEADER · ahead 16w✓Price and the fundamentals both up7 of 9 companies ahead of NIFTY 500 by 5% or more over three months1 is 20% or more behind over a year while earnings grew 20% or more

RS ↑16w · 7/9 >200d (+0) · 7/9 lead (+2) · EPS 7/9↑

Diagnostics, equal-weighted, based at 200 NIFTY 500, same base, same start trailing 12-month earnings per share rising falling

Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 9 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

03 · sector relative strength, before individual stocks

Is Diagnostics outperforming NIFTY 500?

Diagnostics has outperformed NIFTY 500 by 24.9% over the last 52 weeks. Over 13 weeks the gap is a lead of 13%. 8 of 9 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. One Global Service Provider Ltd is the strongest against the sector itself at +54%. Readings are as of 2026-08-22.

+13.0%Sector vs NIFTY 500 · 13 weeks

+24.9%Sector vs NIFTY 500 · 52 weeks

8/9Stocks leading NIFTY 500

4/9Stocks leading sector

Sector metric: 13.5 as of 2026-08-22 · CONSOLIDATION · falling.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Diagnostics has outperformed NIFTY 500 by 24.9% over 52 weeks and 13% over 13 weeks. 8 of 9 covered companies beat NIFTY on Mansfield relative strength, while 4 of 9 beat the sector itself. Dr Lal Pathlabs Ltd leads with revenue of ₹2,892 crore, based on 9 of 9 comparable companies through Jun 2026.

Companies

complete canonical membership

Combined market value

₹77.0K Cr

Dr Lal Pathlabs Ltd

Revenue growing

9/9

positive TTM year-on-year growth

Beating NIFTY 500

8/9

positive Mansfield relative strength

Comparing 5 of 9

04 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%

One Global Service Provider Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 76.3% evidence confidence.

Krsnaa Diagnostics Ltd looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.

Dr Lal Pathlabs Ltd has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.

How this score is built, and what the marks mean

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

Company	Score	Price stage	Growth & earnings/35	Capital efficiency/25	Valuation/20	Relative strength/20
1One Global Service Provider LtdONEGLOBAL	74.9/100Favorable setup76% evidence		31.9/35 Revenue 100% · PAT 100% · OPM change 4 pp 95% evidence	16.8/25 ROCE 87% · OPM 19% 76% evidence	12.5/20 P/E 14.3× · PEG — 50% evidence	13.7/20 RS sector 54% · RS bench 2.2% · 1Y 105.9%12 of 12 weeks ahead 70% evidence
Exact sum: 31.9 + 16.8 + 12.5 + 13.7 = 74.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Thyrocare Technologies LtdTHYROCARE	68.3/100Favorable setup100% evidence	LEADER	27.9/35 Revenue 21.3% · PAT 67.6% · OPM change 2 pp 100% evidence	18.9/25 ROCE 35.4% · OPM 32% 100% evidence	11.2/20 P/E 48.4× · PEG 1.1 100% evidence	10.3/20 RS sector 2.7% · RS bench 20.1% · 1Y 24.3%12 of 12 weeks ahead 100% evidence
Exact sum: 27.9 + 18.9 + 11.2 + 10.3 = 68.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Metropolis Healthcare LtdMETROPOLIS	62.3/100Mixed-positive evidence100% evidence	TURNING	26.3/35 Revenue 21.8% · PAT 33.5% · OPM change 2 pp 100% evidence	11.6/25 ROCE 17.8% · OPM 25% 100% evidence	14.4/20 P/E 58.4× · PEG 1.08 100% evidence	10.0/20 RS sector -0.3% · RS bench 17.2% · 1Y 6.2%8 of 12 weeks ahead 100% evidence
Exact sum: 26.3 + 11.6 + 14.4 + 10 = 62.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Dr Lal Pathlabs LtdLALPATHLAB	58.8/100Mixed-positive evidence100% evidence	LEADER	13.9/35 Revenue 14.3% · PAT 5% · OPM change 2 pp 100% evidence	17.6/25 ROCE 28% · OPM 31% 100% evidence	10.5/20 P/E 57× · PEG 1.29 100% evidence	16.8/20 RS sector 5.5% · RS bench 23.8% · 1Y 17.5%12 of 12 weeks ahead 100% evidence
Exact sum: 13.9 + 17.6 + 10.5 + 16.8 = 58.8 · Decision use: Price leads the evidence: RS versus the benchmark is 23.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
5Vijaya Diagnostic Centre LtdVIJAYA	55.7/100Mixed-positive evidence100% evidence	LEADER	24.0/35 Revenue 20.2% · PAT 23.8% · OPM change 4 pp 100% evidence	15.5/25 ROCE 20.5% · OPM 43% 100% evidence	0.2/20 P/E 82.5× · PEG 4.13 100% evidence	16.0/20 RS sector 14.7% · RS bench 34% · 1Y 35.7%11 of 12 weeks ahead 100% evidence
Exact sum: 24 + 15.5 + 0.2 + 16 = 55.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Suraksha Diagnostic LtdSURAKSHA	52.3/100Mixed-positive evidence80% evidence	TURNING	17.6/35 Revenue 23% · PAT 9.4% · OPM change 2 pp 95% evidence	12.3/25 ROCE 17.3% · OPM 35% 95% evidence	10.0/20 P/E 47.1× · PEG — 15% evidence	12.4/20 RS sector -2.3% · RS bench 15.3% · 1Y 7.6%4 of 12 weeks ahead 100% evidence
Exact sum: 17.6 + 12.3 + 10 + 12.4 = 52.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
73B Blackbio DX Ltd3BBLACKBIO	51.1/100Mixed-positive evidence87% evidence	TURNING	13.8/35 Revenue 54.3% · PAT 14.7% · OPM change -27.8 pp 95% evidence	18.0/25 ROCE 25.5% · OPM 25.4% 95% evidence	10.7/20 P/E 22× · PEG — 50% evidence	8.6/20 RS sector -8.8% · RS bench 8% · 1Y -3.3%3 of 12 weeks ahead 100% evidence
Exact sum: 13.8 + 18 + 10.7 + 8.6 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Vimta Labs LtdVIMTALABS	36.6/100Mixed-negative evidence100% evidence	BREAKING OUT	7.7/35 Revenue 14.2% · PAT 8.1% · OPM change -1 pp 100% evidence	14.3/25 ROCE 25.2% · OPM 34% 100% evidence	5.8/20 P/E 34.8× · PEG 2.04 100% evidence	8.8/20 RS sector -3.9% · RS bench 13.3% · 1Y -28.2%12 of 12 weeks ahead 100% evidence
Exact sum: 7.7 + 14.3 + 5.8 + 8.8 = 36.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Krsnaa Diagnostics LtdKRSNAA	36.5/100Mixed-negative evidence81% evidence	TURNING	10.7/35 Revenue 10.3% · PAT 21% · OPM change -2 pp 95% evidence	8.3/25 ROCE 12.7% · OPM 25% 95% evidence	14.5/20 P/E 18.3× · PEG — 50% evidence	3.0/20 RS sector -18.9% · RS bench -14.1% · 1Y -34.6%0 of 10 weeks ahead 70% evidence
Exact sum: 10.7 + 8.3 + 14.5 + 3 = 36.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.

05 · what price has already done

Market action

One Global Service Provider Ltd has the strongest one-year price move in Diagnostics at +105.9%. Vijaya Diagnostic Centre Ltd leads on Mansfield relative strength against NIFTY at +34%. 8 of 9 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-09-11.

Price and relative strength

Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

06 · the story behind the numbers

Diagnostics — the story behind the numbers

This is the written read behind the Diagnostics figures above — what is actually happening in the sector, in words, with the evidence each claim rests on. It is dated 22 Aug 2026. It also states what would change this read.

How old this read is: This read comes from our fortnightly sector read dated 22 Aug 2026, so the words here and the numbers above them cover the same few weeks.

What would change this read

The volume-led compounder call breaks if, in the quarter after Dr Lal's government reimbursement benefit lapses, sector operating margin falls through the 27-28% normal level while revenue growth also decelerates toward the low-to-mid teens that managements themselves guide — because that would…

Sources: our fortnightly Diagnostics read, 22 Aug 2026.

07 · compare level, then change

Revenue Scale & Growth Durability

Dr Lal Pathlabs Ltd has the highest Revenue among the 9 Diagnostics companies compared here, at ₹2,892 crore. Metropolis Healthcare Ltd is next at ₹1,710 crore. One Global Service Provider Ltd has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Dr Lal Pathlabs Ltd is the scale leader at ₹2,892 crore, 69.1% ahead of Metropolis Healthcare Ltd. One Global Service Provider Ltd's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 163.1% from a ₹513 crore base, with 15 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderDr Lal Pathlabs Ltd · ₹2,892 crore

Gap69.1% versus #2 · Metropolis Healthcare Ltd

Persistence8/8 recent comparable periods

Coverage9/9 companies · 157 observations

Investor read: Dr Lal Pathlabs Ltd is the scale benchmark; One Global Service Provider Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Dr Lal Pathlabs Ltd's growth falls below One Global Service Provider Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenuelargest

1Dr Lal Pathlabs Ltd LALPATHLAB₹2.9K Cr

2Metropolis Healthcare Ltd METROPOLIS₹1.7K Cr

3Thyrocare Technologies Ltd THYROCARE₹877 Cr

4Vijaya Diagnostic Centre Ltd VIJAYA₹857 Cr

5Krsnaa Diagnostics Ltd KRSNAA⚠ unverified₹816 Cr

Revenue growthfastest growers

1One Global Service Provider Ltd ONEGLOBAL100%

23B Blackbio DX Ltd 3BBLACKBIO⚠ unverified54%

3Suraksha Diagnostic Ltd SURAKSHA⚠ unverified23%

4Metropolis Healthcare Ltd METROPOLIS22%

5Thyrocare Technologies Ltd THYROCARE21%

Revenue · company comparison

9/9 level · 9/9 change

On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	Revenue	Revenue growth	Reported
Dr Lal Pathlabs Ltd LALPATHLAB	₹798 Cr	19%	Jun 2026
Metropolis Healthcare Ltd METROPOLIS	₹450 Cr	17%	Jun 2026
Thyrocare Technologies Ltd THYROCARE	₹240 Cr	24%	Jun 2026
Krsnaa Diagnostics Ltd KRSNAA⚠ unverified	₹236 Cr	22%	Jun 2026
Vijaya Diagnostic Centre Ltd VIJAYA	₹231 Cr	23%	Jun 2026
Vimta Labs Ltd VIMTALABS	₹109 Cr	11%	Jun 2026
One Global Service Provider Ltd ONEGLOBAL	₹103 Cr	17%	Jun 2026
Suraksha Diagnostic Ltd SURAKSHA⚠ unverified	₹88 Cr	21%	Jun 2026
3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified	₹33 Cr	51%	Jun 2026

Full 20-quarter history · every available company

Revenue · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹15 Cr

Mar 2023₹18 Cr

Jun 2023₹14 Cr

Sep 2023₹19 Cr

Dec 2023₹18 Cr

Mar 2024₹23 Cr

Jun 2024₹19 Cr

Sep 2024₹29 Cr

Dec 2024₹25 Cr

Mar 2025₹23 Cr

Jun 2025₹22 Cr

Sep 2025₹34 Cr

Dec 2025₹50 Cr

Mar 2026₹35 Cr

Jun 2026₹33 Cr

Dr Lal Pathlabs Ltd · LALPATHLAB

Sep 2021₹498 Cr

Dec 2021₹497 Cr

Mar 2022₹486 Cr

Jun 2022₹503 Cr

Sep 2022₹534 Cr

Dec 2022₹489 Cr

Mar 2023₹491 Cr

Jun 2023₹541 Cr

Sep 2023₹601 Cr

Dec 2023₹539 Cr

Mar 2024₹545 Cr

Jun 2024₹602 Cr

Sep 2024₹660 Cr

Dec 2024₹597 Cr

Mar 2025₹603 Cr

Jun 2025₹670 Cr

Sep 2025₹731 Cr

Dec 2025₹660 Cr

Mar 2026₹703 Cr

Jun 2026₹798 Cr

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹118 Cr

Mar 2023₹133 Cr

Jun 2023₹140 Cr

Sep 2023₹155 Cr

Dec 2023₹158 Cr

Mar 2024₹166 Cr

Jun 2024₹170 Cr

Sep 2024₹186 Cr

Dec 2024₹175 Cr

Mar 2025₹186 Cr

Jun 2025₹193 Cr

Sep 2025₹206 Cr

Dec 2025₹181 Cr

Mar 2026₹193 Cr

Jun 2026₹236 Cr

Metropolis Healthcare Ltd · METROPOLIS

Sep 2021₹303 Cr

Dec 2021₹293 Cr

Mar 2022₹306 Cr

Jun 2022₹280 Cr

Sep 2022₹300 Cr

Dec 2022₹285 Cr

Mar 2023₹283 Cr

Jun 2023₹277 Cr

Sep 2023₹308 Cr

Dec 2023₹291 Cr

Mar 2024₹331 Cr

Jun 2024₹313 Cr

Sep 2024₹350 Cr

Dec 2024₹323 Cr

Mar 2025₹345 Cr

Jun 2025₹386 Cr

Sep 2025₹429 Cr

Dec 2025₹406 Cr

Mar 2026₹425 Cr

Jun 2026₹450 Cr

One Global Service Provider Ltd · ONEGLOBAL

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹8 Cr

Mar 2023₹5 Cr

Jun 2023₹13 Cr

Sep 2023₹12 Cr

Dec 2023₹15 Cr

Mar 2024₹24 Cr

Jun 2024₹14 Cr

Sep 2024₹19 Cr

Dec 2024₹33 Cr

Mar 2025₹55 Cr

Jun 2025₹88 Cr

Sep 2025₹135 Cr

Dec 2025₹141 Cr

Mar 2026₹134 Cr

Jun 2026₹103 Cr

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023₹60 Cr

Dec 2023₹52 Cr

Mar 2024₹55 Cr

Jun 2024₹61 Cr

Sep 2024₹67 Cr

Dec 2024₹60 Cr

Mar 2025₹65 Cr

Jun 2025₹73 Cr

Sep 2025₹79 Cr

Dec 2025₹78 Cr

Mar 2026₹81 Cr

Jun 2026₹88 Cr

Thyrocare Technologies Ltd · THYROCARE

Sep 2021₹176 Cr

Dec 2021₹117 Cr

Mar 2022₹131 Cr

Jun 2022₹128 Cr

Sep 2022₹135 Cr

Dec 2022₹128 Cr

Mar 2023₹136 Cr

Jun 2023₹135 Cr

Sep 2023₹148 Cr

Dec 2023₹135 Cr

Mar 2024₹154 Cr

Jun 2024₹157 Cr

Sep 2024₹177 Cr

Dec 2024₹166 Cr

Mar 2025₹187 Cr

Jun 2025₹193 Cr

Sep 2025₹217 Cr

Dec 2025₹196 Cr

Mar 2026₹224 Cr

Jun 2026₹240 Cr

Vijaya Diagnostic Centre Ltd · VIJAYA

Sep 2021₹113 Cr

Dec 2021₹111 Cr

Mar 2022₹116 Cr

Jun 2022₹104 Cr

Sep 2022₹121 Cr

Dec 2022₹113 Cr

Mar 2023₹121 Cr

Jun 2023₹121 Cr

Sep 2023₹139 Cr

Dec 2023₹133 Cr

Mar 2024₹155 Cr

Jun 2024₹156 Cr

Sep 2024₹183 Cr

Dec 2024₹169 Cr

Mar 2025₹173 Cr

Jun 2025₹188 Cr

Sep 2025₹202 Cr

Dec 2025₹205 Cr

Mar 2026₹219 Cr

Jun 2026₹231 Cr

Vimta Labs Ltd · VIMTALABS

Sep 2021₹75 Cr

Dec 2021₹67 Cr

Mar 2022₹74 Cr

Jun 2022₹79 Cr

Sep 2022₹80 Cr

Dec 2022₹77 Cr

Mar 2023₹82 Cr

Jun 2023₹82 Cr

Sep 2023₹64 Cr

Dec 2023₹73 Cr

Mar 2024₹73 Cr

Jun 2024₹75 Cr

Sep 2024₹85 Cr

Dec 2024₹90 Cr

Mar 2025₹94 Cr

Jun 2025₹98 Cr

Sep 2025₹102 Cr

Dec 2025₹99 Cr

Mar 2026₹109 Cr

Jun 2026₹109 Cr

Revenue growth · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 202318%

Mar 202427%

Jun 202436%

Sep 202452%

Dec 202444%

Mar 2025-2.2%

Jun 202514%

Sep 202516%

Dec 202598%

Mar 202657%

Jun 202651%

Dr Lal Pathlabs Ltd · LALPATHLAB

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-17%

Sep 20227.2%

Dec 2022-1.6%

Mar 20231.0%

Jun 20237.6%

Sep 202313%

Dec 202310%

Mar 202411%

Jun 202411%

Sep 20249.8%

Dec 202411%

Mar 202511%

Jun 202511%

Sep 202511%

Dec 202511%

Mar 202617%

Jun 202619%

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 202334%

Mar 202425%

Jun 202421%

Sep 202420%

Dec 202411%

Mar 202512%

Jun 202514%

Sep 202511%

Dec 20253.4%

Mar 20263.8%

Jun 202622%

Metropolis Healthcare Ltd · METROPOLIS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-14%

Sep 2022-1.0%

Dec 2022-2.7%

Mar 2023-7.5%

Jun 2023-1.1%

Sep 20232.7%

Dec 20232.1%

Mar 202417%

Jun 202413%

Sep 202414%

Dec 202411%

Mar 20254.2%

Jun 202523%

Sep 202523%

Dec 202526%

Mar 202623%

Jun 202617%

One Global Service Provider Ltd · ONEGLOBAL

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 202388%

Mar 2024380%

Jun 20247.7%

Sep 202458%

Dec 2024120%

Mar 2025129%

Jun 2025529%

Sep 2025611%

Dec 2025327%

Mar 2026144%

Jun 202617%

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 202412%

Dec 202415%

Mar 202518%

Jun 202520%

Sep 202518%

Dec 202530%

Mar 202625%

Jun 202621%

Thyrocare Technologies Ltd · THYROCARE

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-22%

Sep 2022-23%

Dec 20229.4%

Mar 20233.8%

Jun 20235.5%

Sep 20239.6%

Dec 20235.5%

Mar 202413%

Jun 202416%

Sep 202420%

Dec 202423%

Mar 202521%

Jun 202523%

Sep 202523%

Dec 202518%

Mar 202620%

Jun 202624%

Vijaya Diagnostic Centre Ltd · VIJAYA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-15%

Sep 20227.1%

Dec 20221.8%

Mar 20234.3%

Jun 202316%

Sep 202315%

Dec 202318%

Mar 202428%

Jun 202429%

Sep 202432%

Dec 202427%

Mar 202512%

Jun 202521%

Sep 202510%

Dec 202521%

Mar 202627%

Jun 202623%

Vimta Labs Ltd · VIMTALABS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 20226.7%

Dec 202215%

Mar 202311%

Jun 20233.8%

Sep 2023-20%

Dec 2023-5.2%

Mar 2024-11%

Jun 2024-8.5%

Sep 202433%

Dec 202423%

Mar 202529%

Jun 202531%

Sep 202520%

Dec 202510%

Mar 202616%

Jun 202611%

08 · compare level, then change

Operating Economics & Margin Trend

Vijaya Diagnostic Centre Ltd has the highest OPM among the 9 Diagnostics companies compared here, at 43%. Suraksha Diagnostic Ltd is next at 35%. One Global Service Provider Ltd has the highest Margin change at +4 percentage points, so level and change sit with different companies. 9 of 9 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Vijaya Diagnostic Centre Ltd leads opm at 43%; One Global Service Provider Ltd leads margin change at +4 percentage points.

LeaderVijaya Diagnostic Centre Ltd · 43%

Gap22.9% versus #2 · Suraksha Diagnostic Ltd

Persistence5/8 recent comparable periods

Coverage9/9 companies · 172 observations

Investor read: Vijaya Diagnostic Centre Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

OPMhighest

1Vijaya Diagnostic Centre Ltd VIJAYA43%

2Suraksha Diagnostic Ltd SURAKSHA⚠ unverified35%

3Vimta Labs Ltd VIMTALABS34%

4Thyrocare Technologies Ltd THYROCARE32%

5Dr Lal Pathlabs Ltd LALPATHLAB31%

Margin changefastest expanders

1One Global Service Provider Ltd ONEGLOBAL+4.0 pp

2Vijaya Diagnostic Centre Ltd VIJAYA+4.0 pp

3Dr Lal Pathlabs Ltd LALPATHLAB+2.0 pp

4Metropolis Healthcare Ltd METROPOLIS+2.0 pp

5Suraksha Diagnostic Ltd SURAKSHA⚠ unverified+2.0 pp

Operating margin · company comparison

9/9 level · 9/9 change

All-company data · latest reported quarter

Company	OPM	Margin change	Reported
Vijaya Diagnostic Centre Ltd VIJAYA	43%	+4.0 pp	Jun 2026
Suraksha Diagnostic Ltd SURAKSHA⚠ unverified	35%	+2.0 pp	Jun 2026
Vimta Labs Ltd VIMTALABS	34%	−1.0 pp	Jun 2026
Thyrocare Technologies Ltd THYROCARE	32%	+2.0 pp	Jun 2026
Dr Lal Pathlabs Ltd LALPATHLAB	31%	+2.0 pp	Jun 2026
3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified	25%	−27.8 pp	Jun 2026
Metropolis Healthcare Ltd METROPOLIS	25%	+2.0 pp	Jun 2026
Krsnaa Diagnostics Ltd KRSNAA⚠ unverified	25%	−2.0 pp	Jun 2026
One Global Service Provider Ltd ONEGLOBAL	19%	+4.0 pp	Jun 2026

Full 20-quarter history · every available company

OPM · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

Sep 202139%

Dec 202149%

Mar 202232%

Jun 202244%

Sep 202253%

Dec 202250%

Mar 202341%

Jun 202345%

Sep 202341%

Dec 202350%

Mar 202443%

Jun 202456%

Sep 202455%

Dec 202459%

Mar 202535%

Jun 202553%

Sep 202543%

Dec 202543%

Mar 202624%

Jun 202625%

Dr Lal Pathlabs Ltd · LALPATHLAB

Sep 202128%

Dec 202122%

Mar 202225%

Jun 202223%

Sep 202227%

Dec 202223%

Mar 202324%

Jun 202327%

Sep 202330%

Dec 202326%

Mar 202427%

Jun 202428%

Sep 202431%

Dec 202426%

Mar 202528%

Jun 202529%

Sep 202531%

Dec 202527%

Mar 202627%

Jun 202631%

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

Sep 202129%

Dec 202128%

Mar 202226%

Jun 202225%

Sep 202225%

Dec 202225%

Mar 202326%

Jun 202322%

Sep 202320%

Dec 202324%

Mar 202426%

Jun 202425%

Sep 202427%

Dec 202426%

Mar 202528%

Jun 202527%

Sep 202529%

Dec 202526%

Mar 202628%

Jun 202625%

Metropolis Healthcare Ltd · METROPOLIS

Sep 202130%

Dec 202126%

Mar 202224%

Jun 202224%

Sep 202226%

Dec 202225%

Mar 202325%

Jun 202323%

Sep 202324%

Dec 202322%

Mar 202424%

Jun 202425%

Sep 202426%

Dec 202422%

Mar 202518%

Jun 202523%

Sep 202525%

Dec 202523%

Mar 202625%

Jun 202625%

One Global Service Provider Ltd · ONEGLOBAL

Sep 202121%

Dec 202132%

Mar 202233%

Jun 20229.1%

Sep 20229.1%

Dec 20229.0%

Mar 202310%

Jun 202311%

Sep 20238.0%

Dec 202314%

Mar 202422%

Jun 202417%

Sep 202416%

Dec 202414%

Mar 202526%

Jun 202515%

Sep 202519%

Dec 202521%

Mar 202618%

Jun 202619%

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 202335%

Dec 202330%

Mar 202435%

Jun 202434%

Sep 202435%

Dec 202431%

Mar 202529%

Jun 202533%

Sep 202531%

Dec 202530%

Mar 202630%

Jun 202635%

Thyrocare Technologies Ltd · THYROCARE

Sep 202151%

Dec 202131%

Mar 202229%

Jun 202228%

Sep 202223%

Dec 202222%

Mar 202318%

Jun 202326%

Sep 202325%

Dec 202323%

Mar 202422%

Jun 202427%

Sep 202427%

Dec 202425%

Mar 202530%

Jun 202530%

Sep 202533%

Dec 202530%

Mar 202634%

Jun 202632%

Vijaya Diagnostic Centre Ltd · VIJAYA

Sep 202145%

Dec 202143%

Mar 202241%

Jun 202238%

Sep 202240%

Dec 202239%

Mar 202341%

Jun 202340%

Sep 202341%

Dec 202339%

Mar 202441%

Jun 202439%

Sep 202442%

Dec 202440%

Mar 202540%

Jun 202539%

Sep 202541%

Dec 202542%

Mar 202644%

Jun 202643%

Vimta Labs Ltd · VIMTALABS

Sep 202126%

Dec 202131%

Mar 202231%

Jun 202230%

Sep 202232%

Dec 202228%

Mar 202330%

Jun 202329%

Sep 202326%

Dec 202331%

Mar 202436%

Jun 202435%

Sep 202435%

Dec 202437%

Mar 202535%

Jun 202535%

Sep 202534%

Dec 202535%

Mar 202636%

Jun 202634%

Margin change · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

Sep 2021−31.7 pp

Dec 2021−10.0 pp

Mar 2022−12.9 pp

Jun 2022−11.4 pp

Sep 2022+13.6 pp

Dec 2022+1.5 pp

Mar 2023+9.0 pp

Jun 2023+0.8 pp

Sep 2023−12.4 pp

Dec 2023+0.2 pp

Mar 2024+1.8 pp

Jun 2024+11.3 pp

Sep 2024+14.9 pp

Dec 2024+9.2 pp

Mar 2025−7.8 pp

Jun 2025−3.1 pp

Sep 2025−12.0 pp

Dec 2025−16.2 pp

Mar 2026−11.2 pp

Jun 2026−27.8 pp

Dr Lal Pathlabs Ltd · LALPATHLAB

Sep 2021−1.1 pp

Dec 2021−8.7 pp

Mar 2022−3.4 pp

Jun 2022−7.8 pp

Sep 2022−1.5 pp

Dec 2022+1.0 pp

Mar 2023−0.9 pp

Jun 2023+3.6 pp

Sep 2023+3.1 pp

Dec 2023+3.0 pp

Mar 2024+3.0 pp

Jun 2024+1.0 pp

Sep 2024+1.0 pp

Dec 20240.0 pp

Mar 2025+1.0 pp

Jun 2025+1.0 pp

Sep 20250.0 pp

Dec 2025+1.0 pp

Mar 2026−1.0 pp

Jun 2026+2.0 pp

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

Sep 2021+1.0 pp

Dec 2021+9.1 pp

Mar 2022−8.8 pp

Jun 2022−6.7 pp

Sep 2022−4.6 pp

Dec 2022−3.2 pp

Mar 2023+0.1 pp

Jun 2023−2.6 pp

Sep 2023−4.9 pp

Dec 2023−1.0 pp

Mar 20240.0 pp

Jun 2024+3.0 pp

Sep 2024+7.0 pp

Dec 2024+2.0 pp

Mar 2025+2.0 pp

Jun 2025+2.0 pp

Sep 2025+2.0 pp

Dec 20250.0 pp

Mar 20260.0 pp

Jun 2026−2.0 pp

Metropolis Healthcare Ltd · METROPOLIS

Sep 2021−1.7 pp

Dec 2021−5.8 pp

Mar 2022−8.6 pp

Jun 2022−6.9 pp

Sep 2022−3.5 pp

Dec 2022−0.7 pp

Mar 2023+0.5 pp

Jun 2023−1.5 pp

Sep 2023−2.3 pp

Dec 2023−3.0 pp

Mar 2024−1.0 pp

Jun 2024+2.0 pp

Sep 2024+2.0 pp

Dec 20240.0 pp

Mar 2025−6.0 pp

Jun 2025−2.0 pp

Sep 2025−1.0 pp

Dec 2025+1.0 pp

Mar 2026+7.0 pp

Jun 2026+2.0 pp

One Global Service Provider Ltd · ONEGLOBAL

Sep 2021−75.7 pp

Dec 2021−32.1 pp

Mar 2022−29.0 pp

Jun 2022−0.8 pp

Sep 2022−11.9 pp

Dec 2022−23.4 pp

Mar 2023−22.8 pp

Jun 2023+1.9 pp

Sep 2023−1.1 pp

Dec 2023+5.0 pp

Mar 2024+12.0 pp

Jun 2024+6.0 pp

Sep 2024+8.0 pp

Dec 20240.0 pp

Mar 2025+4.0 pp

Jun 2025−2.0 pp

Sep 2025+3.0 pp

Dec 2025+7.0 pp

Mar 2026−8.0 pp

Jun 2026+4.0 pp

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 20240.0 pp

Dec 2024+1.0 pp

Mar 2025−6.0 pp

Jun 2025−1.0 pp

Sep 2025−4.0 pp

Dec 2025−1.0 pp

Mar 2026+1.0 pp

Jun 2026+2.0 pp

Thyrocare Technologies Ltd · THYROCARE

Sep 2021+10.2 pp

Dec 2021−4.7 pp

Mar 2022−6.3 pp

Jun 2022−15.0 pp

Sep 2022−27.2 pp

Dec 2022−9.2 pp

Mar 2023−10.8 pp

Jun 2023−2.1 pp

Sep 2023+1.6 pp

Dec 2023+1.0 pp

Mar 2024+4.0 pp

Jun 2024+1.0 pp

Sep 2024+2.0 pp

Dec 2024+2.0 pp

Mar 2025+8.0 pp

Jun 2025+3.0 pp

Sep 2025+6.0 pp

Dec 2025+5.0 pp

Mar 2026+4.0 pp

Jun 2026+2.0 pp

Vijaya Diagnostic Centre Ltd · VIJAYA

Sep 2021+0.1 pp

Dec 2021−3.3 pp

Mar 2022−7.4 pp

Jun 2022−8.1 pp

Sep 2022−5.0 pp

Dec 2022−4.2 pp

Mar 2023−0.2 pp

Jun 2023+1.8 pp

Sep 2023+0.6 pp

Dec 20230.0 pp

Mar 20240.0 pp

Jun 2024−1.0 pp

Sep 2024+1.0 pp

Dec 2024+1.0 pp

Mar 2025−1.0 pp

Jun 20250.0 pp

Sep 2025−1.0 pp

Dec 2025+2.0 pp

Mar 2026+4.0 pp

Jun 2026+4.0 pp

Vimta Labs Ltd · VIMTALABS

Sep 2021−0.6 pp

Dec 2021+2.5 pp

Mar 2022+3.0 pp

Jun 2022+2.6 pp

Sep 2022+5.7 pp

Dec 2022−3.0 pp

Mar 2023−1.0 pp

Jun 2023−1.0 pp

Sep 2023−6.0 pp

Dec 2023+3.0 pp

Mar 2024+6.0 pp

Jun 2024+6.0 pp

Sep 2024+9.0 pp

Dec 2024+6.0 pp

Mar 2025−1.0 pp

Jun 20250.0 pp

Sep 2025−1.0 pp

Dec 2025−2.0 pp

Mar 2026+1.0 pp

Jun 2026−1.0 pp

09 · compare level, then change

Profit Scale & Acceleration

Dr Lal Pathlabs Ltd has the highest Net profit among the 9 Diagnostics companies compared here, at ₹545 crore. Metropolis Healthcare Ltd is next at ₹203 crore. One Global Service Provider Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Dr Lal Pathlabs Ltd leads with ₹545 crore of TTM profit, 168.5% above Metropolis Healthcare Ltd. One Global Service Provider Ltd shows ≥100% on the scoring scale (184.6% uncapped) growth from a ₹74 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderDr Lal Pathlabs Ltd · ₹545 crore

Gap168.5% versus #2 · Metropolis Healthcare Ltd

Persistence6/8 recent comparable periods

Coverage9/9 companies · 157 observations

Investor read: Dr Lal Pathlabs Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profitlargest

1Dr Lal Pathlabs Ltd LALPATHLAB₹545 Cr

2Metropolis Healthcare Ltd METROPOLIS₹203 Cr

3Vijaya Diagnostic Centre Ltd VIJAYA₹187 Cr

4Thyrocare Technologies Ltd THYROCARE₹176 Cr

5Krsnaa Diagnostics Ltd KRSNAA⚠ unverified₹98 Cr

Profit growthfastest growers

1One Global Service Provider Ltd ONEGLOBAL100%

2Thyrocare Technologies Ltd THYROCARE68%

3Metropolis Healthcare Ltd METROPOLIS34%

4Vijaya Diagnostic Centre Ltd VIJAYA24%

5Krsnaa Diagnostics Ltd KRSNAA⚠ unverified21%

Net profit · company comparison

9/9 level · 9/9 change

All-company data · latest reported quarter

Company	Net profit	Profit growth	Reported
Dr Lal Pathlabs Ltd LALPATHLAB	₹170 Cr	27%	Jun 2026
Metropolis Healthcare Ltd METROPOLIS	₹57 Cr	27%	Jun 2026
Vijaya Diagnostic Centre Ltd VIJAYA	₹53 Cr	36%	Jun 2026
Thyrocare Technologies Ltd THYROCARE	₹51 Cr	34%	Jun 2026
Vimta Labs Ltd VIMTALABS	₹21 Cr	11%	Jun 2026
Krsnaa Diagnostics Ltd KRSNAA⚠ unverified	₹17 Cr	-19%	Jun 2026
One Global Service Provider Ltd ONEGLOBAL	₹14 Cr	40%	Jun 2026
Suraksha Diagnostic Ltd SURAKSHA⚠ unverified	₹13 Cr	44%	Jun 2026
3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified	₹9 Cr	-29%	Jun 2026

Full 20-quarter history · every available company

Net profit · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹8 Cr

Mar 2023₹5 Cr

Jun 2023₹7 Cr

Sep 2023₹8 Cr

Dec 2023₹9 Cr

Mar 2024₹9 Cr

Jun 2024₹11 Cr

Sep 2024₹15 Cr

Dec 2024₹13 Cr

Mar 2025₹8 Cr

Jun 2025₹13 Cr

Sep 2025₹15 Cr

Dec 2025₹22 Cr

Mar 2026₹10 Cr

Jun 2026₹9 Cr

Dr Lal Pathlabs Ltd · LALPATHLAB

Sep 2021₹95 Cr

Dec 2021₹57 Cr

Mar 2022₹61 Cr

Jun 2022₹58 Cr

Sep 2022₹72 Cr

Dec 2022₹54 Cr

Mar 2023₹57 Cr

Jun 2023₹84 Cr

Sep 2023₹111 Cr

Dec 2023₹82 Cr

Mar 2024₹86 Cr

Jun 2024₹108 Cr

Sep 2024₹131 Cr

Dec 2024₹98 Cr

Mar 2025₹156 Cr

Jun 2025₹134 Cr

Sep 2025₹152 Cr

Dec 2025₹91 Cr

Mar 2026₹132 Cr

Jun 2026₹170 Cr

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹14 Cr

Mar 2023₹19 Cr

Jun 2023₹15 Cr

Sep 2023₹10 Cr

Dec 2023₹13 Cr

Mar 2024₹19 Cr

Jun 2024₹18 Cr

Sep 2024₹20 Cr

Dec 2024₹19 Cr

Mar 2025₹21 Cr

Jun 2025₹21 Cr

Sep 2025₹24 Cr

Dec 2025₹15 Cr

Mar 2026₹42 Cr

Jun 2026₹17 Cr

Metropolis Healthcare Ltd · METROPOLIS

Sep 2021₹58 Cr

Dec 2021₹41 Cr

Mar 2022₹40 Cr

Jun 2022₹33 Cr

Sep 2022₹40 Cr

Dec 2022₹36 Cr

Mar 2023₹33 Cr

Jun 2023₹29 Cr

Sep 2023₹36 Cr

Dec 2023₹27 Cr

Mar 2024₹37 Cr

Jun 2024₹38 Cr

Sep 2024₹47 Cr

Dec 2024₹31 Cr

Mar 2025₹29 Cr

Jun 2025₹45 Cr

Sep 2025₹53 Cr

Dec 2025₹42 Cr

Mar 2026₹51 Cr

Jun 2026₹57 Cr

One Global Service Provider Ltd · ONEGLOBAL

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹1 Cr

Mar 2023₹0 Cr

Jun 2023₹1 Cr

Sep 2023₹1 Cr

Dec 2023₹1 Cr

Mar 2024₹4 Cr

Jun 2024₹2 Cr

Sep 2024₹2 Cr

Dec 2024₹3 Cr

Mar 2025₹11 Cr

Jun 2025₹10 Cr

Sep 2025₹20 Cr

Dec 2025₹22 Cr

Mar 2026₹18 Cr

Jun 2026₹14 Cr

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023₹8 Cr

Dec 2023₹5 Cr

Mar 2024₹6 Cr

Jun 2024₹8 Cr

Sep 2024₹10 Cr

Dec 2024₹6 Cr

Mar 2025₹7 Cr

Jun 2025₹9 Cr

Sep 2025₹9 Cr

Dec 2025₹7 Cr

Mar 2026₹6 Cr

Jun 2026₹13 Cr

Thyrocare Technologies Ltd · THYROCARE

Sep 2021₹78 Cr

Dec 2021₹22 Cr

Mar 2022₹21 Cr

Jun 2022₹22 Cr

Sep 2022₹15 Cr

Dec 2022₹15 Cr

Mar 2023₹12 Cr

Jun 2023₹17 Cr

Sep 2023₹20 Cr

Dec 2023₹15 Cr

Mar 2024₹17 Cr

Jun 2024₹24 Cr

Sep 2024₹26 Cr

Dec 2024₹19 Cr

Mar 2025₹22 Cr

Jun 2025₹38 Cr

Sep 2025₹48 Cr

Dec 2025₹28 Cr

Mar 2026₹49 Cr

Jun 2026₹51 Cr

Vijaya Diagnostic Centre Ltd · VIJAYA

Sep 2021₹28 Cr

Dec 2021₹25 Cr

Mar 2022₹24 Cr

Jun 2022₹17 Cr

Sep 2022₹23 Cr

Dec 2022₹16 Cr

Mar 2023₹28 Cr

Jun 2023₹26 Cr

Sep 2023₹34 Cr

Dec 2023₹26 Cr

Mar 2024₹34 Cr

Jun 2024₹32 Cr

Sep 2024₹42 Cr

Dec 2024₹35 Cr

Mar 2025₹35 Cr

Jun 2025₹39 Cr

Sep 2025₹43 Cr

Dec 2025₹43 Cr

Mar 2026₹48 Cr

Jun 2026₹53 Cr

Vimta Labs Ltd · VIMTALABS

Sep 2021₹10 Cr

Dec 2021₹12 Cr

Mar 2022₹12 Cr

Jun 2022₹12 Cr

Sep 2022₹13 Cr

Dec 2022₹10 Cr

Mar 2023₹13 Cr

Jun 2023₹12 Cr

Sep 2023₹6 Cr

Dec 2023₹9 Cr

Mar 2024₹12 Cr

Jun 2024₹12 Cr

Sep 2024₹15 Cr

Dec 2024₹22 Cr

Mar 2025₹18 Cr

Jun 2025₹19 Cr

Sep 2025₹20 Cr

Dec 2025₹18 Cr

Mar 2026₹21 Cr

Jun 2026₹21 Cr

Profit growth · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 20236.4%

Mar 202469%

Jun 202457%

Sep 202496%

Dec 202459%

Mar 2025-8.5%

Jun 202512%

Sep 20251.1%

Dec 202566%

Mar 202622%

Jun 2026-29%

Dr Lal Pathlabs Ltd · LALPATHLAB

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-56%

Sep 2022-24%

Dec 2022-5.3%

Mar 2023-6.6%

Jun 202345%

Sep 202354%

Dec 202352%

Mar 202451%

Jun 202429%

Sep 202418%

Dec 202420%

Mar 202581%

Jun 202524%

Sep 202516%

Dec 2025-7.1%

Mar 2026-15%

Jun 202627%

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023-7.1%

Mar 20240.0%

Jun 202420%

Sep 2024100%

Dec 202446%

Mar 202511%

Jun 202517%

Sep 202520%

Dec 2025-21%

Mar 2026100%

Jun 2026-19%

Metropolis Healthcare Ltd · METROPOLIS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-56%

Sep 2022-31%

Dec 2022-12%

Mar 2023-18%

Jun 2023-12%

Sep 2023-10%

Dec 2023-25%

Mar 202412%

Jun 202431%

Sep 202431%

Dec 202415%

Mar 2025-22%

Jun 202518%

Sep 202513%

Dec 202535%

Mar 202676%

Jun 202627%

One Global Service Provider Ltd · ONEGLOBAL

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 20230.0%

Mar 2024—

Jun 2024100%

Sep 2024100%

Dec 2024200%

Mar 2025175%

Jun 2025400%

Sep 2025900%

Dec 2025633%

Mar 202664%

Jun 202640%

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 202425%

Dec 202420%

Mar 202517%

Jun 202513%

Sep 2025-10%

Dec 202517%

Mar 2026-14%

Jun 202644%

Thyrocare Technologies Ltd · THYROCARE

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-61%

Sep 2022-81%

Dec 2022-32%

Mar 2023-43%

Jun 2023-23%

Sep 202333%

Dec 20230.0%

Mar 202442%

Jun 202441%

Sep 202430%

Dec 202427%

Mar 202529%

Jun 202558%

Sep 202585%

Dec 202547%

Mar 2026123%

Jun 202634%

Vijaya Diagnostic Centre Ltd · VIJAYA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-48%

Sep 2022-18%

Dec 2022-36%

Mar 202317%

Jun 202353%

Sep 202348%

Dec 202363%

Mar 202421%

Jun 202423%

Sep 202424%

Dec 202435%

Mar 20252.9%

Jun 202522%

Sep 20252.4%

Dec 202523%

Mar 202637%

Jun 202636%

Vimta Labs Ltd · VIMTALABS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 202230%

Dec 2022-17%

Mar 20238.3%

Jun 20230.0%

Sep 2023-54%

Dec 2023-10%

Mar 2024-7.7%

Jun 20240.0%

Sep 2024150%

Dec 2024144%

Mar 202550%

Jun 202558%

Sep 202533%

Dec 2025-18%

Mar 202617%

Jun 202611%

10 · compare level, then change

Return On Capital Employed

One Global Service Provider Ltd has the highest ROCE among the 9 Diagnostics companies compared here, at 87%. Thyrocare Technologies Ltd is next at 35.4%. The same company also holds the highest ROCE change, at +31 percentage points. 9 of 9 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: One Global Service Provider Ltd leads ROCE at 87%, 51.6 percentage points above Thyrocare Technologies Ltd. One Global Service Provider Ltd has the strongest latest improvement at +31 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderOne Global Service Provider Ltd · 87%

Gap145.8% versus #2 · Thyrocare Technologies Ltd

PersistenceNot enough history

Coverage9/9 companies · 119 observations

Investor read: One Global Service Provider Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

ROCEhighest

1One Global Service Provider Ltd ONEGLOBAL87%

2Thyrocare Technologies Ltd THYROCARE35%

3Dr Lal Pathlabs Ltd LALPATHLAB28%

43B Blackbio DX Ltd 3BBLACKBIO⚠ unverified26%

5Vimta Labs Ltd VIMTALABS25%

ROCE changefastest improvers

1One Global Service Provider Ltd ONEGLOBAL+31.0 pp

2Thyrocare Technologies Ltd THYROCARE+8.3 pp

3Metropolis Healthcare Ltd METROPOLIS+2.4 pp

4Vijaya Diagnostic Centre Ltd VIJAYA−0.5 pp

5Dr Lal Pathlabs Ltd LALPATHLAB−1.0 pp

Return on capital · company comparison

9/9 level · 9/9 change

All-company data · latest reported quarter

Company	ROCE	ROCE change	Reported
Thyrocare Technologies Ltd THYROCARE	32%	+8.3 pp	Jun 2026
Vimta Labs Ltd VIMTALABS	24%	−3.0 pp	Jun 2026
Dr Lal Pathlabs Ltd LALPATHLAB	23%	−1.0 pp	Jun 2026
Vijaya Diagnostic Centre Ltd VIJAYA	18%	−0.5 pp	Jun 2026
3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified	15%	−2.6 pp	Jun 2026
Metropolis Healthcare Ltd METROPOLIS	15%	+2.4 pp	Jun 2026
Suraksha Diagnostic Ltd SURAKSHA⚠ unverified	14%	−2.1 pp	Jun 2026
Krsnaa Diagnostics Ltd KRSNAA⚠ unverified	7.8%	−2.6 pp	Jun 2026

Full 20-quarter history · every available company

ROCE · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

Sep 202139%

Dec 2021—

Mar 202225%

Jun 2022—

Sep 202218%

Dec 2022—

Mar 202315%

Jun 2023—

Sep 202312%

Dec 202319%

Mar 202414%

Jun 202423%

Sep 202418%

Dec 202428%

Mar 202518%

Jun 202526%

Sep 202515%

Dec 202526%

Mar 202615%

Jun 2026—

Dr Lal Pathlabs Ltd · LALPATHLAB

Sep 202134%

Dec 2021—

Mar 202225%

Jun 2022—

Sep 202219%

Dec 2022—

Mar 202318%

Jun 2023—

Sep 202321%

Dec 202326%

Mar 202424%

Jun 202429%

Sep 202424%

Dec 202430%

Mar 202524%

Jun 202531%

Sep 202524%

Dec 202529%

Mar 202623%

Jun 2026—

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

Sep 202112%

Dec 2021—

Mar 202212%

Jun 2022—

Sep 20229.4%

Dec 2022—

Mar 20238.5%

Jun 2023—

Sep 20237.7%

Dec 202310%

Mar 20247.8%

Jun 202411%

Sep 20249.9%

Dec 202414%

Mar 202510%

Jun 202514%

Sep 202511%

Dec 202514%

Mar 20267.8%

Jun 2026—

Metropolis Healthcare Ltd · METROPOLIS

Sep 202134%

Dec 2021—

Mar 202223%

Jun 2022—

Sep 202218%

Dec 2022—

Mar 202317%

Jun 2023—

Sep 202315%

Dec 202315%

Mar 202415%

Jun 202416%

Sep 202416%

Dec 202417%

Mar 202512%

Jun 202515%

Sep 202513%

Dec 202516%

Mar 202615%

Jun 2026—

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 202416%

Jun 202417%

Sep 202417%

Dec 202418%

Mar 202516%

Jun 202519%

Sep 202514%

Dec 202518%

Mar 202614%

Jun 2026—

Thyrocare Technologies Ltd · THYROCARE

Sep 202145%

Dec 202141%

Mar 202237%

Jun 2022—

Sep 202221%

Dec 202218%

Mar 202315%

Jun 2023—

Sep 202316%

Dec 202318%

Mar 202417%

Jun 202420%

Sep 202421%

Dec 202425%

Mar 202524%

Jun 202530%

Sep 202531%

Dec 202537%

Mar 202632%

Jun 2026—

Vijaya Diagnostic Centre Ltd · VIJAYA

Sep 202127%

Dec 2021—

Mar 202223%

Jun 2022—

Sep 202217%

Dec 2022—

Mar 202315%

Jun 2023—

Sep 202317%

Dec 202322%

Mar 202418%

Jun 202422%

Sep 202419%

Dec 202423%

Mar 202518%

Jun 202523%

Sep 202517%

Dec 202522%

Mar 202618%

Jun 2026—

Vimta Labs Ltd · VIMTALABS

Sep 202120%

Dec 2021—

Mar 202222%

Jun 2022—

Sep 202224%

Dec 202227%

Mar 202321%

Jun 202324%

Sep 202317%

Dec 202319%

Mar 202418%

Jun 202418%

Sep 202421%

Dec 202424%

Mar 202522%

Jun 202527%

Sep 202521%

Dec 202524%

Mar 202620%

Jun 202624%

ROCE change · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−21.0 pp

Dec 2022—

Mar 2023−10.2 pp

Jun 2023—

Sep 2023−5.8 pp

Dec 2023—

Mar 2024−0.4 pp

Jun 2024—

Sep 2024+5.8 pp

Dec 2024+8.4 pp

Mar 2025+3.7 pp

Jun 2025+2.8 pp

Sep 2025−2.3 pp

Dec 2025−1.5 pp

Mar 2026−2.6 pp

Jun 2026—

Dr Lal Pathlabs Ltd · LALPATHLAB

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−14.8 pp

Dec 2022—

Mar 2023−6.8 pp

Jun 2023—

Sep 2023+1.7 pp

Dec 2023—

Mar 2024+5.7 pp

Jun 2024—

Sep 2024+3.6 pp

Dec 2024+3.7 pp

Mar 2025+0.7 pp

Jun 2025+2.4 pp

Sep 2025−0.5 pp

Dec 2025−0.6 pp

Mar 2026−1.0 pp

Jun 2026—

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−2.8 pp

Dec 2022—

Mar 2023−3.5 pp

Jun 2023—

Sep 2023−1.7 pp

Dec 2023—

Mar 2024−0.7 pp

Jun 2024—

Sep 2024+2.2 pp

Dec 2024+3.4 pp

Mar 2025+2.6 pp

Jun 2025+3.0 pp

Sep 2025+0.9 pp

Dec 2025−0.1 pp

Mar 2026−2.6 pp

Jun 2026—

Metropolis Healthcare Ltd · METROPOLIS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−16.2 pp

Dec 2022—

Mar 2023−6.4 pp

Jun 2023—

Sep 2023−2.8 pp

Dec 2023—

Mar 2024−1.6 pp

Jun 2024—

Sep 2024+0.2 pp

Dec 2024+1.7 pp

Mar 2025−2.5 pp

Jun 2025−1.1 pp

Sep 2025−2.9 pp

Dec 2025−1.0 pp

Mar 2026+2.4 pp

Jun 2026—

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025−0.1 pp

Jun 2025+2.1 pp

Sep 2025−2.6 pp

Dec 2025−0.6 pp

Mar 2026−2.1 pp

Jun 2026—

Thyrocare Technologies Ltd · THYROCARE

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−24.0 pp

Dec 2022−23.1 pp

Mar 2023−22.2 pp

Jun 2023—

Sep 2023−4.8 pp

Dec 2023−0.2 pp

Mar 2024+1.8 pp

Jun 2024—

Sep 2024+5.1 pp

Dec 2024+6.8 pp

Mar 2025+7.1 pp

Jun 2025+9.9 pp

Sep 2025+10.1 pp

Dec 2025+12.8 pp

Mar 2026+8.3 pp

Jun 2026—

Vijaya Diagnostic Centre Ltd · VIJAYA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−10.0 pp

Dec 2022—

Mar 2023−8.0 pp

Jun 2023—

Sep 2023−0.7 pp

Dec 2023—

Mar 2024+2.7 pp

Jun 2024—

Sep 2024+2.1 pp

Dec 2024+0.9 pp

Mar 2025+0.2 pp

Jun 2025+0.4 pp

Sep 2025−1.5 pp

Dec 2025−1.2 pp

Mar 2026−0.5 pp

Jun 2026—

Vimta Labs Ltd · VIMTALABS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+3.1 pp

Dec 2022—

Mar 2023−0.9 pp

Jun 2023—

Sep 2023−6.7 pp

Dec 2023−8.0 pp

Mar 2024−3.1 pp

Jun 2024−6.1 pp

Sep 2024+4.3 pp

Dec 2024+5.7 pp

Mar 2025+3.3 pp

Jun 2025+8.9 pp

Sep 2025+0.1 pp

Dec 20250.0 pp

Mar 2026−1.3 pp

Jun 2026−3.0 pp

11 · compare level, then change

Valuation Against Growth & Quality

Metropolis Healthcare Ltd has the lowest PEG among the 9 Diagnostics companies compared here, at 1.08×. Thyrocare Technologies Ltd is next at 1.1×. One Global Service Provider Ltd has the lowest P/E at 14.3×, so level and change sit with different companies. 5 of 9 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Metropolis Healthcare Ltd has the lowest comparable PEG at 1.08×, 1.8% below Thyrocare Technologies Ltd. Only 5 of 9 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderMetropolis Healthcare Ltd · 1.08×

Gap1.8% versus #2 · Thyrocare Technologies Ltd

Persistence0/8 recent comparable periods

Coverage5/9 companies · 43 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

PEGlowest PEG

1Metropolis Healthcare Ltd METROPOLIS1.1

2Thyrocare Technologies Ltd THYROCARE1.1

3Dr Lal Pathlabs Ltd LALPATHLAB1.3

4Vimta Labs Ltd VIMTALABS2.0

5Vijaya Diagnostic Centre Ltd VIJAYA4.1

P/Elowest P/E

1One Global Service Provider Ltd ONEGLOBAL14.3

2Krsnaa Diagnostics Ltd KRSNAA⚠ unverified18.3

33B Blackbio DX Ltd 3BBLACKBIO⚠ unverified22.0

4Vimta Labs Ltd VIMTALABS34.8

5Suraksha Diagnostic Ltd SURAKSHA⚠ unverified47.1

Valuation · company comparison

5/9 level · 9/9 change

All-company data · latest reported quarter

Company	PEG	P/E	Reported
Vijaya Diagnostic Centre Ltd VIJAYA	4.1	81.3	Jun 2026
Vimta Labs Ltd VIMTALABS	2.0	33.9	Jun 2026
Dr Lal Pathlabs Ltd LALPATHLAB	1.3	53.9	Jun 2026
Thyrocare Technologies Ltd THYROCARE	1.1	51.2	Jun 2026
Metropolis Healthcare Ltd METROPOLIS	1.1	57.3	Jun 2026
Krsnaa Diagnostics Ltd KRSNAA⚠ unverified	—	17.2	Jun 2026
Suraksha Diagnostic Ltd SURAKSHA⚠ unverified	—	44.0	Jun 2026
3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified	—	17.0	Jun 2026
One Global Service Provider Ltd ONEGLOBAL	—	20.9	Jun 2026

Full 20-quarter history · every available company

PEG · reported quarter history

Dr Lal Pathlabs Ltd · LALPATHLAB

Sep 20212.8

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 20233.3

Mar 20241.6

Jun 20241.3

Sep 20241.6

Dec 20241.9

Mar 20251.9

Jun 20251.4

Sep 20251.5

Dec 2025—

Mar 20261.3

Jun 2026—

Metropolis Healthcare Ltd · METROPOLIS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20223.5

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 20247.7

Jun 2024—

Sep 2024—

Dec 20244.7

Mar 2025—

Jun 2025—

Sep 2025—

Dec 20252.4

Mar 2026—

Jun 20261.1

Thyrocare Technologies Ltd · THYROCARE

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 20241.0

Jun 20244.8

Sep 20241.9

Dec 20242.0

Mar 20251.2

Jun 20252.0

Sep 20251.5

Dec 20251.1

Mar 2026—

Jun 2026—

Vijaya Diagnostic Centre Ltd · VIJAYA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 20233.0

Jun 2023—

Sep 2023—

Dec 20234.5

Mar 20241.4

Jun 20241.5

Sep 20242.1

Dec 20242.8

Mar 20253.1

Jun 20253.6

Sep 20253.4

Dec 20255.2

Mar 20261.5

Jun 20264.1

Vimta Labs Ltd · VIMTALABS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 20220.4

Dec 20220.5

Mar 20232.2

Jun 20231.6

Sep 2023—

Dec 2023—

Mar 20240.4

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 20250.9

Dec 2025—

Mar 20261.7

Jun 20262.0

P/E · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

Sep 20214.0

Dec 20218.0

Mar 20229.3

Jun 20228.8

Sep 202213.0

Dec 202215.6

Mar 202313.4

Jun 202312.7

Sep 202320.9

Dec 202321.4

Mar 202420.2

Jun 202427.6

Sep 202430.0

Dec 202439.7

Mar 202528.9

Jun 202525.8

Sep 202523.9

Dec 202524.4

Mar 202617.4

Jun 202617.0

Dr Lal Pathlabs Ltd · LALPATHLAB

Sep 202182.2

Dec 202178.8

Mar 202259.9

Jun 202249.0

Sep 202277.4

Dec 202276.0

Mar 202362.6

Jun 202378.8

Sep 202379.8

Dec 202371.3

Mar 202457.2

Jun 202464.9

Sep 202471.6

Dec 202461.4

Mar 202549.7

Jun 202547.9

Sep 202552.1

Dec 202544.0

Mar 202640.5

Jun 202653.9

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

Sep 2021-57.5

Dec 202158.7

Mar 202222.4

Jun 202223.9

Sep 202225.7

Dec 202222.7

Mar 202323.6

Jun 202329.6

Sep 202334.2

Dec 202338.4

Mar 202434.0

Jun 202434.0

Sep 202444.3

Dec 202440.5

Mar 202533.6

Jun 202529.0

Sep 202532.0

Dec 202528.0

Mar 202622.1

Jun 202617.2

Metropolis Healthcare Ltd · METROPOLIS

Sep 202164.1

Dec 202172.8

Mar 202245.5

Jun 202236.4

Sep 202246.0

Dec 202243.9

Mar 202342.8

Jun 202353.5

Sep 202354.1

Dec 202364.5

Mar 202470.8

Jun 202479.2

Sep 202481.7

Dec 202471.3

Mar 202554.2

Jun 202568.2

Sep 202576.5

Dec 202572.9

Mar 202651.0

Jun 202657.3

One Global Service Provider Ltd · ONEGLOBAL

Sep 20215.6

Dec 20217.4

Mar 202217.8

Jun 202232.5

Sep 202222.5

Dec 202220.9

Mar 202313.0

Jun 202316.6

Sep 202315.9

Dec 202310.8

Mar 202415.6

Jun 202414.3

Sep 202416.2

Dec 202425.9

Mar 202522.9

Jun 202514.2

Sep 202510.7

Dec 202524.3

Mar 202620.0

Jun 202620.9

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 20242.2

Mar 20252.4

Jun 202548.5

Sep 202543.8

Dec 202544.2

Mar 202636.9

Jun 202644.0

Thyrocare Technologies Ltd · THYROCARE

Sep 202139.8

Dec 202128.8

Mar 202221.4

Jun 202218.9

Sep 202226.1

Dec 202241.0

Mar 202331.1

Jun 202342.5

Sep 202350.1

Dec 202352.5

Mar 202447.6

Jun 202447.6

Sep 202455.7

Dec 202458.5

Mar 202541.0

Jun 202557.6

Sep 202556.0

Dec 202557.4

Mar 202640.5

Jun 202651.2

Vijaya Diagnostic Centre Ltd · VIJAYA

Sep 202131.2

Dec 202131.3

Mar 202223.6

Jun 202230.8

Sep 202249.9

Dec 202249.7

Mar 202349.4

Jun 202357.0

Sep 202354.6

Dec 202366.8

Mar 202456.9

Jun 202463.6

Sep 202471.8

Dec 202482.0

Mar 202572.7

Jun 202570.4

Sep 202569.1

Dec 202569.6

Mar 202655.6

Jun 202681.3

Vimta Labs Ltd · VIMTALABS

Sep 202119.8

Dec 202126.4

Mar 202219.2

Jun 202217.1

Sep 202216.3

Dec 202219.9

Mar 202314.8

Jun 202319.2

Sep 202327.3

Dec 202321.5

Mar 202422.8

Jun 202425.9

Sep 202425.9

Dec 202439.1

Mar 202535.7

Jun 202529.0

Sep 202545.1

Dec 202536.4

Mar 202623.6

Jun 202633.9

12 · before the conclusion, check the blind spots

What can make this comparison misleading?

This Diagnostics comparison names 5 specific ways its own evidence can mislead, all listed below. All 9 companies here report on comparable dates, so no rank carries a stale marker. 3 draw at least one figure from a second feed with too little overlap to cross-check. A high growth rate can still be a low-base artefact.

Keep these limits visible

A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
3 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.

13 · evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 9 Diagnostics companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-09-11. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.

FundamentalsThrough Jun 2026 · up to 20 quarters per company

Market dataThrough 2026-09-11 · weekly price and relative-strength history

Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.

Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.

Source standing5 cross-checked · 4 unverified · 0 withheld, of 9 graded companies.

How a second data feed is admitted, and what happens when it disagrees

A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.

14 · questions investors ask, short speakable answers

Diagnostics company comparison FAQs

These 24 answers restate the Diagnostics comparison above in question form. Every one is computed from the same 9 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-09-11. Nothing here is estimated, and none of it is a recommendation.

Is the Diagnostics sector outperforming NIFTY 500?

Diagnostics has outperformed NIFTY 500 by 24.9% over 52 weeks and 13% over 13 weeks. 8 of 9 covered companies beat NIFTY on Mansfield relative strength, while 4 of 9 beat the sector itself.

Which Diagnostics company is largest by revenue?

Dr Lal Pathlabs Ltd leads with revenue of ₹2,892 crore, based on 9 of 9 comparable companies through Jun 2026.

Which Diagnostics company is growing fastest?

One Global Service Provider Ltd has the fastest current revenue growth at 100%, across 9 of 9 comparable companies.

Which Diagnostics company has the strongest 4-Factor Sector Score?

One Global Service Provider Ltd ranks first at 74.9/100 with 76.3% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Diagnostics company has the lowest comparable PEG?

Metropolis Healthcare Ltd has the lowest comparable PEG at 1.08, among 5 of 9 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Diagnostics comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

Is there a Nifty Diagnostics index?

NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Diagnostics, this page builds its own equal-weight basket of 9 listed Diagnostics companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.

Which are the best Diagnostics stocks in India?

Ranked by this page's four-factor score, One Global Service Provider Ltd places first among 9 listed Diagnostics companies, followed by Thyrocare Technologies Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

How many Diagnostics stocks are listed in India?

This comparison covers 9 listed Diagnostics companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.

Which Diagnostics company is the biggest?

Dr Lal Pathlabs Ltd is the largest, with trailing-twelve-month revenue of ₹2,892 crore, ahead of Metropolis Healthcare Ltd at ₹1,710 crore. That covers 9 of 9 companies with comparable reporting through Jun 2026.

Which Diagnostics company has the best profit margins?

Vijaya Diagnostic Centre Ltd has the highest operating margin at 43%, from 9 of 9 comparable companies. One Global Service Provider Ltd shows the biggest recent improvement, at +4 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Diagnostics company makes the most profit?

Dr Lal Pathlabs Ltd earns the most, at ₹545 crore of trailing-twelve-month net profit, from 9 of 9 comparable companies. One Global Service Provider Ltd has the fastest profit growth at the ≥100% scoring cap, though growth off a small or recovering profit base overstates how much has actually changed.

Which Diagnostics company earns the highest return on capital?

One Global Service Provider Ltd leads on return on capital employed at 87%, across 9 of 9 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Diagnostics stock is the cheapest?

On PEG — where a LOWER number is cheaper — Metropolis Healthcare Ltd screens cheapest at 1.08×. Only 5 of 9 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Is the Diagnostics sector beating the market?

Diagnostics has outperformed NIFTY 500 by 24.9% over the last 52 weeks and 13% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 8 of 9 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Diagnostics stock has the strongest price momentum?

Vijaya Diagnostic Centre Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Diagnostics company scores highest for research priority?

One Global Service Provider Ltd scores 74.9 out of 100 with 76.3% evidence confidence, from 31.9 points on growth and earnings, 16.8 on capital efficiency, 12.5 on valuation and 13.7 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Diagnostics companies does this comparison cover, and over what period?

It compares 9 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Diagnostics sector?

The 9 Diagnostics companies on this page carry ₹76,965 crore of combined market value. Dr Lal Pathlabs Ltd is the largest at ₹32,042 crore, about 42% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-09-17.

What is the Diagnostics sector's P/E ratio?

The median price-to-earnings ratio across the 9 Diagnostics companies on this page is 47.1×, measured on the 9 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-09-17.

How is the Diagnostics sector performing?

8 of the 9 covered Diagnostics companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 24.9% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-09-17.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

About

Not SEBI Registered !! Not Investment advice !!